# Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

> **NCT06366490** · PHASE1 · RECRUITING · sponsor: **PhotonPharma, Inc.** · enrollment: 8 (estimated)

## Conditions studied

- Ovarian Cancer
- Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** Innocell Autologous Cellular Immunotherapy

## Key facts

- **NCT ID:** NCT06366490
- **Lead sponsor:** PhotonPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-12
- **Primary completion:** 2026-11
- **Final completion:** 2026-12
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06366490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06366490, "Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06366490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*